(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 13.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.15%.
Immunocore Holdings's revenue in 2025 is $333,581,000.On average, 19 Wall Street analysts forecast IMCR's revenue for 2025 to be $20,255,698,157, with the lowest IMCR revenue forecast at $18,224,753,345, and the highest IMCR revenue forecast at $21,625,568,675. On average, 19 Wall Street analysts forecast IMCR's revenue for 2026 to be $22,048,535,662, with the lowest IMCR revenue forecast at $19,686,551,367, and the highest IMCR revenue forecast at $24,727,996,366.
In 2027, IMCR is forecast to generate $24,971,629,370 in revenue, with the lowest revenue forecast at $17,903,258,248 and the highest revenue forecast at $31,262,384,225.